Savara
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.About SVRA
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis.
SVRA Key Statistics
Stock Snapshot
Savara(SVRA) stock is priced at $6.11, giving the company a market capitalization of 1.24B. It carries a P/E multiple of -12.02.
During the trading session on 2025-12-17, Savara(SVRA) shares reached a daily high of $6.60 and a low of $5.96. At a current price of $6.11, the stock is +2.5% higher than the low and still -7.4% under the high.
Trading volume for Savara(SVRA) stock has reached 3.53M, versus its average volume of 4.82M.
The stock's 52-week range extends from a low of $1.89 to a high of $7.01.
The stock's 52-week range extends from a low of $1.89 to a high of $7.01.
SVRA News
Savara (SVRA) just picked up a meaningful intellectual property win, with the European Patent Office signaling its intention to grant a patent on the liquid for...
Savara Inc. recently announced that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled GM-CSF...
Savara (SVRA) announced the European Patent Office notified the company of its intention to grant a patent application covering the liquid formulation of Molbre...